This chapter briefly discusses the primary cutaneous melanoma and its incidence, risk factors, diagnosis, prognosis and treatment objectives. It also describes the recommendations for surgical excision margins based on the Breslow thickness of the melanoma. The management of patients with lentigo maligna (LM) or lentigo maligna melanoma (LMM), and the role of sentinel lymph-node biopsy are discussed in detail. The chapter also discusses the therapies to improve overall survival in patients with metastatic malignant melanoma. It also discusses the question: Does antisense therapy against B-cell lymphoma 2 improve outcomes in patients with metastatic melanoma. Developments in the systemic treatment of melanoma have resulted in improved survival for advance metastatic melanoma (Stage IV). The role of cytotoxic chemotherapeutic agents, as monotherapy and in combination regimens, is limited in initial treatment for metastatic melanoma.
- Antisense therapy
- Cytotoxic chemotherapeutic agents
- Lentigo maligna melanoma (LMM)
- Metastatic malignant melanoma
- Primary cutaneous melanoma
- Sentinel lymph-node biopsy
ASJC Scopus subject areas